The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 2 trial of 5-imino-13-deoxydoxorubicin (GPX-150) in metastatic and non-resectable soft tissue sarcomas.
 
Brian Andrew Van Tine
Consulting or Advisory Role - Advaxis; Caris Life Sciences; DFINE; EMD Serono; GlaxoSmithKline; Johnson & Johnson; Lilly/ImClone; Novartis; Threshold Pharmaceuticals
Speakers' Bureau - Caris Life Sciences; DFINE; GlaxoSmithKline
Research Funding - Morphotek; Polaris
 
Mark Agulnik
Consulting or Advisory Role - EMD Serono; Five Prime Therapeutics; GlaxoSmithKline; Janssen; Novartis
Speakers' Bureau - GlaxoSmithKline; Novartis
 
Richard D. Olson
Employment - Gem Pharmaceuticals
Leadership - Gem Pharmaceuticals
Stock and Other Ownership Interests - Gem Pharmaceuticals
Consulting or Advisory Role - Gem Pharmaceuticals
Research Funding - Gem Pharmaceuticals
Patents, Royalties, Other Intellectual Property - Gem Pharmaceuticals
 
Gerald M. Walsh
Employment - Gem Pharmaceuticals
Leadership - Gem Pharmaceuticals
Stock and Other Ownership Interests - Gem Pharmaceuticals
Patents, Royalties, Other Intellectual Property - Gem Pharmaceuticals
 
Arthur Klausner
Employment - Jade Therapeutics
Leadership - Cennerv Pharma; Gem Pharmaceuticals; Jade Therapeutics
Stock and Other Ownership Interests - Gem Pharmaceuticals
Consulting or Advisory Role - Cennerv Pharma; Gem Pharmaceuticals; Jade Therapeutics
 
Mohammed M. Milhem
Consulting or Advisory Role - Amgen; EMD Serono; Novartis